News | January 07, 2023
KIMS invests further in Sarvejana Healthcare
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.
Transformation to pure-play Innovative Medicines company nears completion
Advancing to IND-enabling studies with multiple drug candidates
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
Researchers from the Tel Aviv University successfully engineer the world's first 3D human spinal cord tissue transplant
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Subscribe To Our Newsletter & Stay Updated
